How to Choose a Dietary Supplement Contract Manufacturer: 10 Questions to Ask

Choosing the wrong dietary supplement contract manufacturer (CMO) is one of the most expensive mistakes a brand can make. A poor fit means delayed launches, quality failures, regulatory liability, and — in serious cases — FDA warning letters or market recalls attached to your brand name. Yet most supplement brands approach CMO selection without a structured framework, relying on price comparisons, Google searches, and word-of-mouth referrals that reveal little about manufacturing capability, quality culture, or regulatory track record.

This guide provides 10 specific, actionable questions to ask any contract manufacturing organization (CMO) before signing a manufacturing agreement. For each question, we explain what to ask, why it matters, what a strong answer looks like, and the red flags that should stop you from moving forward.

Question 1: What Is Your cGMP Certification Status, and Who Audits You?

Why it matters: Current Good Manufacturing Practice (cGMP) compliance — codified in 21 CFR Part 111 for dietary supplements — is the regulatory foundation of supplement quality. FDA registration is not the same as cGMP compliance. Registration is self-declaration and requires no verification; cGMP compliance is assessed through FDA inspections and third-party audits. The gap between claiming compliance and demonstrating it separates reliable manufacturers from liability risks.

What to ask:

• What is your FDA registration number, and can I look it up at FDA.gov?
• When was your most recent FDA inspection, and what was the outcome?
• Do you hold third-party cGMP certifications (NSF, Informed Sport, UL, NPA)?
• Are you open to client facility audits before and during the manufacturing relationship?

Strong answer: FDA-registered with a verifiable registration number, documented FDA inspection history, clean inspection letter or credible response to any observations, openness to client audits. Third-party certifications (NSF, Informed Sport) provide independent verification of cGMP compliance beyond self-declaration.

Red flag: Vague answers about “following GMP guidelines” without specific certification status or inspection records. Reluctance to allow client facility audits. Inability to provide or verify their FDA registration number at FDA.gov/food/facility-registration.

Question 2: What Dosage Forms Do You Currently Manufacture — and at What Scale?

Why it matters: Contract manufacturers vary enormously in format capability. A facility built for capsule and tablet production does not have the specialized equipment to produce oral dissolving film (ODF) strips, suppositories, or stick packs at production scale. Claiming capability is not the same as demonstrating active production history. A CMO that has never commercially produced your specific dosage form is a significant risk.

What to ask:

• What dosage forms are currently in commercial production at your facility?
• Can you provide product samples or reference SKUs in the specific format I need?
• What specialized equipment do you operate for my target format?
• What is the production capacity (units per day or batch size) for my dosage form?

Strong answer: Specific active SKUs in your target dosage form with references. Detailed equipment listings for the format you need. Honest distinction between core production capability and experimental or pilot-scale capability.

Red flag: “We can do anything” positioning without references for your specific format. Reluctance to provide samples. Quoting capability that turns out to be pilot-scale or outsourced to a subcontractor.

Question 3: What Is Your In-House Testing Laboratory Capability?

Why it matters: Quality control testing — raw material identity testing, in-process testing, and finished product release testing — is required under 21 CFR Part 111. CMOs that outsource all analytical testing introduce timeline risk (contract lab turnaround adds days or weeks) and chain-of-custody complexity that can complicate batch documentation. In-house labs with validated analytical methods are the gold standard for GMP supplement manufacturing.

What to ask:

• What analytical testing equipment is in-house (HPLC, GC, ICP-MS, FTIR, dissolution)?
• What tests are performed in-house versus at third-party contract laboratories?
• Do you have validated methods for potency assay of my specific active ingredients?
• Do you maintain in-house stability chambers for accelerated and real-time stability studies?

Strong answer: In-house HPLC for potency assay, dissolution testing apparatus, microbial testing capability, and stability chambers. Validated analytical methods for your specific actives. Clear documentation of what is tested in-house versus outsourced, with rationale.

Red flag: All analytical testing outsourced with no in-house capability. Inability to describe validated test methods for your specific active ingredients. No in-house stability testing capability when your product requires an accelerated stability study.

Question 4: What Are Your Minimum Order Quantities (MOQ) by Dosage Form?

Why it matters: MOQ requirements vary significantly across CMOs and dosage forms, and misalignment creates real business problems. High-throughput manufacturers serving large consumer packaged goods brands may require 50,000 to 100,000 units per run — appropriate for established brands with validated demand, but catastrophic inventory exposure for a brand launching its first SKU. MOQ should match your launch volume, not your CMO’s preferred batch economics.

What to ask:

• What is the minimum order quantity for each dosage form you produce?
• Is the MOQ set by unit count, batch weight, or revenue minimum?
• Can MOQ be reduced for development batches or initial launch runs?
• What drives the minimum — is it cGMP sampling requirements, equipment economics, or pricing margin?

Strong answer: Specific MOQ figures per format, with a clear explanation of what sets the minimum. Willingness to discuss small-batch programs for new product development. Transparent pricing at different volume tiers.

Red flag: MOQ so high it requires you to fund inventory beyond your realistic sell-through. Unwillingness to explain what drives the minimum. Pricing structures that make small batches prohibitively expensive to discourage them without saying so.

Question 5: What Does Your Formulation Development Process Look Like?

Why it matters: Many brands need a manufacturing partner for both formulation and production — not just a filling house to process an existing formula. Whether you are developing a novel supplement from a concept, adapting a clinical formulation for commercial production, or improving an existing formula, the CMO’s R&D capability determines whether you get a scientifically sound, differentiated product or a generic formula with your label on it.

What to ask:

• Do you have in-house formulation scientists? What are their qualifications?
• What does your development workflow look like — from concept through pilot batch?
• How are development batches priced and scoped?
• What documentation do you provide at each development milestone?
• Who owns the intellectual property developed during formulation?

Strong answer: In-house formulation team with documented development phases: feasibility assessment, prototype, pilot batch, scale-up, process validation. Clear IP provisions specifying that custom formulas belong to the client. Defined milestone documentation including batch records, stability protocols, and manufacturing specifications.

Red flag: Ambiguous IP terms — any language suggesting the CMO retains rights to or will reuse your custom formula. No in-house R&D capability (the CMO is a broker, not a manufacturer). Inability to describe a structured development process with defined deliverables.

Question 6: How Do You Handle Raw Material Sourcing and Supplier Qualification?

Why it matters: Supplement adulteration, contamination, and mislabeled ingredient failures predominantly trace back to raw material sourcing problems. Under 21 CFR Part 111, CMOs are required to qualify ingredient suppliers and verify raw material identity and purity before use. How rigorously this is executed separates manufacturers with genuine quality systems from those with paperwork-only compliance.

What to ask:

• Do you source raw materials for clients, or does the client supply ingredients?
• How do you qualify new ingredient suppliers? Do you maintain an Approved Vendor List (AVL)?
• What testing do you perform on incoming raw materials (identity, potency, contaminants)?
• Can I specify or approve the ingredient suppliers you use for my product?
• What is the country of origin for key active ingredients in my formula?

Strong answer: Documented AVL with qualification criteria including supplier audits, CoA review, and independent third-party testing history. Incoming raw material testing that includes identity verification (FTIR, HPLC) independent of supplier-provided CoAs. Willingness to accommodate client-specified suppliers. Transparency about ingredient origin.

Red flag: Sole reliance on supplier-provided Certificates of Analysis without independent identity testing. No documented AVL. Inability to identify country of origin for key actives. All ingredients sourced from a single overseas region without domestic alternatives.

Question 7: What Is Your Typical Timeline From Signed Agreement to Delivered Product?

Why it matters: Timeline failures are one of the top complaints brands have about supplement CMOs and can be catastrophic when you have retail shelf commitments, crowdfunding campaigns, investor milestones, or seasonal launch windows. A CMO that consistently misses production schedules is a business continuity risk regardless of product quality.

What to ask:

• What is the typical timeline from purchase order to finished goods delivery for a stock formula? For a custom formulation?
• What are the most common causes of timeline delays, and how do you communicate them?
• Do you guarantee production slots once scheduled?
• Can you provide references specifically for on-time delivery performance?

Strong answer: Specific, documented timelines by product type. Honest discussion of delay causes (ingredient lead times, stability hold requirements, QC testing turnaround) and mitigation protocols. Written production slot commitments. References who can independently confirm on-time delivery track record.

Red flag: Vague “depends on complexity” timelines without concrete estimates. No discussion of delay causes or how they are communicated. Inability to provide references specifically for delivery performance.

Question 8: Can You Support International Regulatory Requirements?

Why it matters: If your brand sells or plans to sell internationally — particularly in Australia, Canada, the United Kingdom, or the European Union — your manufacturer’s documentation must satisfy the regulatory requirements of each target market. FDA registration alone does not automatically satisfy Australian TGA, Health Canada, or EU requirements. Many U.S. CMOs have no international regulatory experience and cannot provide the specific documentation required for foreign market entry.

What to ask:

• Have you supported brands exporting to Australia, Canada, the UK, or EU markets?
• Do you hold TGA GMP recognition for Australian market access?
• Can you provide manufacturing documentation formatted for Health Canada NHP applications?
• What international regulatory expertise does your team have?

Strong answer: Documented experience supporting international market exports. TGA GMP recognition (or application history) for Australian brands. Demonstrated ability to provide the specific manufacturing documentation required for NHP applications (Canada) or TGA product listing (Australia). In-house or accessible regulatory expertise for target markets.

Red flag: No international regulatory experience. Vague assurances that “FDA registration should be sufficient” for overseas markets without confirming specific requirements. Inability to provide examples of supporting international brand clients.

Question 9: What Happens if a Production Batch Fails Quality Control?

Why it matters: Batch failures happen in supplement manufacturing. A mature quality system has defined non-conformance procedures, root cause analysis protocols, and corrective action processes for when they occur. What distinguishes a reliable CMO partner from a risky one is not whether failures happen — it is how quickly they are identified, how transparently they are communicated, and who bears responsibility for the cost.

What to ask:

• What is your non-conformance and CAPA (corrective and preventive action) process?
• How quickly do you communicate a batch failure to the client?
• Who is financially responsible for failed batches — and does that depend on the failure cause?
• What is your rework and reprocessing policy for salvageable batches?
• Can you share the outcome of any past CAPA actions relevant to my product type?

Strong answer: Documented non-conformance procedure with defined root cause investigation and CAPA process. Communication timeline of 24 to 48 hours for critical failures. Clear contractual language distinguishing manufacturer-caused failures from client-specification or raw material failures, with corresponding liability assignment. References who can speak to how failures were handled.

Red flag: No documented CAPA process. All failure costs placed on the client regardless of cause. No communication protocol for quality events. Reluctance to discuss failure scenarios, rates, or past CAPA outcomes.

Question 10: What Specialty Capabilities Differentiate You From Other CMOs?

Why it matters: The best CMO for your brand is not the largest or cheapest — it is the one whose specialization most closely matches your product’s formulation requirements and market positioning. A CMO with proprietary technology relevant to your product can provide genuine advantages in performance, stability, and differentiation that a generalist filling house cannot. Knowing what makes a CMO distinctive lets you assess fit rather than just compliance.

What to ask:

• What proprietary formulation technologies or delivery platforms do you own?
• Are there specific product categories or formulation challenges you are uniquely positioned to solve?
• What patents or trade secrets are relevant to my product type?
• What do your best clients say differentiates you from other manufacturers they have worked with?

Strong answer: Specific proprietary technologies with clear applicability to your product category. A patent portfolio demonstrating investment in formulation innovation. Ability to articulate how their unique capability translates into better product outcomes for brands in your category.

Red flag: No differentiation beyond “we are FDA-registered and competitively priced.” Inability to articulate any proprietary capability or category-specific expertise. Generalist positioning that suggests they manufacture anything for anyone without depth in any area.

The CMO Evaluation Scorecard

After asking these 10 questions, use this framework to assess and compare candidates:

Criteria	Strong	Adequate	Weak / Red Flag
cGMP status	Clean inspection + third-party cert	FDA-registered, inspection history available	Vague compliance claims, no records
Dosage form expertise	Active SKUs + samples in your format	Some production history, limited examples	Claimed capability, no demonstrated production
In-house testing	HPLC, micro, dissolution, stability in-house	Basic in-house, outsources advanced testing	All testing outsourced
MOQ alignment	MOQ at or below your launch order	Slightly above, flexible on first order	MOQ requires excessive inventory commitment
IP protection	Explicit client ownership in contract	Standard confidentiality, IP negotiable	Ambiguous or unfavorable IP terms
Timeline reliability	References confirm on-time track record	Generally on-time with acknowledged exceptions	No references, vague timeline estimates
International support	TGA recognition, Health Canada docs available	Limited international experience	No international regulatory capability

Frequently Asked Questions About Choosing a Supplement Contract Manufacturer

What is the difference between a CMO and a CDMO for dietary supplements?

A CMO (contract manufacturing organization) provides manufacturing services using formulas the client has already developed. A CDMO (contract development and manufacturing organization) provides both formulation development and manufacturing under one roof — taking a brand from concept through commercial production. For emerging supplement brands without an in-house R&D team, a CDMO is typically the better fit because it eliminates the need to coordinate formulation development and manufacturing across separate vendors.

Is FDA registration enough, or does the facility need NSF or Informed Sport certification?

FDA registration is the minimum regulatory requirement for a U.S. dietary supplement manufacturer. NSF, Informed Sport, and similar third-party certifications provide additional verification of cGMP compliance and, in the case of Informed Sport, batch-level testing for substances banned in professional sport. For brands targeting the sports nutrition market, Informed Sport certification at the batch level is increasingly expected by retailers and consumers. For general supplement brands, FDA registration plus a verifiable inspection history is the baseline; third-party certifications are a meaningful differentiator.

How long does it typically take to launch a dietary supplement with a contract manufacturer?

Using a private label stock formulation, brands can typically launch in 8 to 12 weeks from purchase order. Custom formulation development — developing a proprietary formula from concept — adds significant time: 16 to 24 weeks is typical for most supplement formats, with some stability-intensive products requiring 30 to 36 weeks before the first commercial production run. Regulatory review, label approval, and Supplement Facts panel verification add time on top of manufacturing lead time regardless of which path you choose.

What documents should a contract manufacturer provide with each production run?

A cGMP-compliant supplement CMO should provide a Certificate of Analysis (CoA) covering active ingredient potency, identity verification, microbial limits, and heavy metals (where applicable), along with a batch manufacturing record documenting the full production history of the lot. Some manufacturers also provide a Certificate of Conformance, in-process testing records, and raw material CoAs from ingredient suppliers. These documents are required for DSHEA compliance and are necessary for international regulatory submissions to TGA (Australia) and Health Canada.

Can a contract manufacturer help me with supplement labeling and regulatory compliance?

Most experienced CDMOs provide label guidance as part of their service — including Supplement Facts panel formatting, serving size determination, DSHEA-compliant structure/function claim guidance, and net quantity declarations. Some also support label design through in-house or partner design resources. However, regulatory interpretation and final label approval responsibility rests with the brand owner. For complex products or specific market claims, engaging a regulatory consultant in addition to the CMO is advisable.

Why Atrium Scientific Stands Out Against This Framework

Atrium Scientific Group is an FDA-registered, cGMP-certified contract development and manufacturing organization (CDMO) in Garden Grove, California (Orange County). Atrium was designed specifically for the segment of the supplement market most underserved by both large pharmaceutical CDMOs (too expensive, high MOQ) and generalist capsule fillers (no specialty capability).

Against the 10-question CMO evaluation framework:

• cGMP status: FDA-registered facility in Garden Grove, CA; eligible for client facility audits; cGMP-compliant across all manufacturing zones
• Dosage form depth: ODF sublingual films, suppositories, capsules, stick packs, teeth whitening strips, and personal care topicals — all in commercial production at one facility
• In-house testing: Analytical labs with stability testing, in-house QC for potency and microbial testing
• Low MOQ: 3,000 units across all formats — one of the lowest from a U.S.-based multi-format CDMO
• IP ownership: Custom formulas belong to the client; Atrium does not reuse client-specific formulations
• International regulatory support: TGA GMP recognition documentation for Australian exports; Health Canada NHP documentation for Canadian market entry
• Specialty technology: Patented nano-encapsulation and complexation technology for enhanced bioavailability, taste masking, and controlled dissolution in ODF and topical formulations — developed by polymer science PhDs

Ready to evaluate Atrium Scientific as your supplement contract manufacturer? Contact our team to schedule a discovery call, request a facility overview, or get a quote for your product.

Page last updated: April 22, 2026